Department of Vascular Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands.
Department of Vascular Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands.
Ann Vasc Surg. 2021 May;73:321-328. doi: 10.1016/j.avsg.2020.10.029. Epub 2020 Nov 26.
Subclavian or innominate artery stenosis (SAS) may cause upper extremity and cerebral ischemia. In patients with symptomatic subclavian or innominate artery stenosis, percutaneous transluminal angioplasty is the treatment of first choice. When percutaneous transluminal angioplasty is technically restricted or unsuccessful, an extrathoracic bypass grafting, such as an axillo-axillary bypass can be considered. The patency rate of axillo-axillary bypass is often questioned. The aim of this study was to assess long-term outcomes of patients undergoing axillo-axillary bypass for subclavian or innominate artery stenosis (SAS) and to provide a literature overview.
In this single-center study, data from patients who underwent axillo-axillary bypass for symptomatic SAS between 2002 and 2018 were retrospectively analyzed. Bypass material was Dacron® (54%) or polytetrafluoroethylene (PTFE) (46%). Primary outcome was graft patency and secondary outcome was the occurrence of mortality and stroke. In addition, a systematic literature search was performed in MEDLINE and EMBASE databases including all studies describing patency of axillo-axillary bypass.
In total, 28 axillo-axillary bypasses had been performed. Cumulative primary, primary-assisted, and secondary patency rates at one year were 89%, 93%, and 96%, respectively. Cumulative primary, primary-assisted, and secondary patency rates at five years were 76%, 84%, and 87%, respectively. The primary-assisted patency rates at five years for Dacron® and PTFE were 93% and 73%, respectively. A total of four primary axillo-axillary bypass occlusions occurred (14%), with a mean of 12 months (range, 0.4-25) after operation. The 30-day mortality was 7%; one patient died after a stroke and one died of a myocardial infarction. At the first postoperative follow-up control, 22 of the 26 remaining patients (85%) had relief of symptoms. The literature search included 7 studies and described a one-year primary patency range of 93-100% (n = 137) and early postoperative adverse events included death (range, 0-13%) and stroke (range, 0-5%).
Patency rates of axillo-axillary bypasses for patients with a symptomatic SAS are good. However, the procedural complication rate in this series is high and attention should be paid to intervention indication.
锁骨下动脉或无名动脉狭窄(SAS)可能导致上肢和脑缺血。对于有症状的锁骨下或无名动脉狭窄患者,经皮腔内血管成形术是首选治疗方法。当经皮腔内血管成形术在技术上受到限制或不成功时,可以考虑体外旁路移植,例如腋-腋旁路。腋-腋旁路的通畅率经常受到质疑。本研究的目的是评估因锁骨下或无名动脉狭窄(SAS)而行腋-腋旁路的患者的长期结果,并提供文献综述。
在这项单中心研究中,回顾性分析了 2002 年至 2018 年间因症状性 SAS 而行腋-腋旁路的患者的数据。旁路材料为膨体聚四氟乙烯(ePTFE)(46%)或涤纶(Dacron®)(54%)。主要结局是移植物通畅率,次要结局是死亡率和卒中的发生。此外,还在 MEDLINE 和 EMBASE 数据库中进行了系统的文献检索,包括描述腋-腋旁路通畅率的所有研究。
共进行了 28 例腋-腋旁路手术。1 年时的累积主要通畅率、主要辅助通畅率和次要通畅率分别为 89%、93%和 96%。5 年时的累积主要通畅率、主要辅助通畅率和次要通畅率分别为 76%、84%和 87%。Dacron®和 ePTFE 的 5 年主要辅助通畅率分别为 93%和 73%。共有 4 例主要腋-腋旁路闭塞(14%),术后平均 12 个月(范围:0.4-25)发生。30 天死亡率为 7%;1 例患者死于卒中和 1 例患者死于心肌梗死。在第一次术后随访时,26 例剩余患者中的 22 例(85%)症状缓解。文献检索包括 7 项研究,描述了 1 年的主要通畅率范围为 93%-100%(n=137),术后早期不良事件包括死亡(范围:0%-13%)和卒中(范围:0%-5%)。
对于有症状的 SAS 患者,腋-腋旁路的通畅率良好。然而,本研究系列中的手术并发症发生率较高,应注意介入指征。